From Crisis to Cure: PolyBio is supporting top HIV researchers to pivot into the study and treatment of Long COVID. Watch the full video to learn how this collaboration is being maximized & driving forward innovative research: https://t.co/Fc6rLyNsab

11/ “We are so glad to help optimally move the first Long COVID clinical trial of an immunotherapy forward” says Dr. Amy Proal, President of PolyBio Research Foundation. “Supporting the immune response in participants has true potential to help clear SARS-CoV-2 reservoirs in Long

Ready to make your mark? At AEG, we turn ambition into action. Let’s bring your dreams to life. Join us

10/ This allows the trial to expand into an experimental medicine study that helps to validate Bioshield’s mechanism of action in addition to documenting potential symptom improvement in participants administered the drug.

9/ Key is that measurement of the persistence metrics at multiple trial timepoints will determine potential clearance of SARS-CoV-2 from INTERRUPT-LC participants.

8/ Optimal measurement of viral persistence metrics in samples will be informed by a recent viewpoint published in Lancet Infectious Diseases by 36 members of the PolyBio Long COVID Research Consortium.

Every marketing leader I talk to is facing the same challenge: Scale 📶 The demand for content has exploded, but the systems behind it haven’t kept up. Teams are expected to launch more campaigns, in more markets, with more data, all while maintaining brand integrity and speed.

7/ PolyBio funds will help support the cost of gut tissue, lymph node tissue, and blood sample collection and analysis from trial participants at multiple timepoints.

6/ The pilot clinical trial to evaluate Bioshield in Long COVID will be performed via the UCSF LIINC site: a Long COVID program also supported by PolyBio. The trial is an exploratory pilot study of 20 Long COVID participants.

5/ If this model is correct, then enhancing the immune response to better target persistent virus replication or residual virus-infected cells across tissues should result in symptom improvement.

4/ By restoring this immune cell function, the therapy may improve the ability of Long COVID patients to clear persistent SARS-CoV-2 virus. More specifically, there is growing evidence that persistence of the SARS-CoV-2 virus and immune dysregulation are drivers of Long COVID.

I haven’t been as present covering the Kings lately — not from disinterest, but because I’ve been pouring my energy into something that feels like the foundation of everything I care about. While I rarely talk politics online, I’ve quietly built my path in international

3/ The trial – INTERRUPT-LC – is an industry sponsored pilot trial of ImmunityBio’sBioShield™: an immunotherapy platform centered on ANKTIVA®, a IL-15 agonist designed to activate and proliferate natural killer cells and T cells and CD8+T cells.

2/ This funding will expand advanced testing to measure if the SARS-CoV-2 virus remains in the body of trial participants, giving researchers crucial insight into treatment response.

1/ BREAKING: PolyBio adds key resources to Long Covid immunotherapy pilot trial analysis PolyBio is proud to announce a donation to UCSF to support analysis around a new Long COVID immunotherapy clinical trial, INTERRUPT-LC. https://t.co/AGvRnkJQr5

3/ Watch the full video on the PolyBio-supported UCSF Long Covid research team here:

2/ PolyBio CEO Dr. Amy Proal, and collaborators Dr.s Putrino, Peluso & Iwasaki are making the most of these academic-industry partnerships to drive forward Long Covid therapeutics; via their participation in the SPEAR study group. Partnering with Invivyd, the group will guide

Apple $AAPL just set itself up for the ultimate "prove it" moment. iPhone 17 demand? They say it's incredible. Next quarter's forecast? Boldest in years. The pressure? Immense. January earnings either validate everything or becomes very awkward...

“To get rid of HIV, we need to go after the virus, we need to go after the inflammation, we need the immune system to work better,” says Dr. Steve Deeks. “Over the last 20 years we have built up all these collaborations with industry, funders, and other academic groups trying to

Don’t miss this opportunity to learn about the impact of pathogens like SARS-CoV-2 on our body systems! PolyBio’s Fall symposium is less than 2 weeks away, on November 14th. Sign up now to hear about innovative projects from around the globe! https://t.co/PaB4kZaYsL

3/ Watch the full video exploring how UCSF researchers, with the support of PolyBio, have been able to make enormous strides in Long Covid research:

2/ The PASC Tissue Program is the first in the world to comprehensively sample multiple tissues including gut, lymph node, cerebrospinal fluid, and bone marrow to determine if tissue-based viral persistence contributes to Long COVID and can be altered via interventions targeting

What was going on here?

UCSF researcher Dr. Tim Henrich describes how the PolyBio-supported PASC tissue program is changing the game: “What we’ve really been finding is that SARS-CoV-2 is able to persist for a long period of time in various tissues across the body… the gut, the bone marrow, the brain,

5/ MICROFLUIDIC CAPTURE TO IDENTIFY POTENTIAL VIRAL PARTICLES IN LONG COVID BLOOD Dr. Shannon Stott 2:10-2:20 PM ET To analyze Long COVID blood samples with a novel microfluidic technology that isolates rare, intact SARS-CoV-2 viral particles from complex biofluids. If viral